These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8545811)

  • 1. Efficacy of apraclonidine ophthalmic solution (iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
    Flach AJ
    Surv Ophthalmol; 1995; 40(1):84-5. PubMed ID: 8545811
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
    Gramer E; Busche S; Kampik A; Parsons D
    Graefes Arch Clin Exp Ophthalmol; 1995 Jan; 233(1):13-20. PubMed ID: 7721118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
    Nishimoto JH; Chang FW; Tang IH; Kolin T
    J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questions concerning the role of apraclonidine in the management of glaucoma.
    Robin AL
    Arch Ophthalmol; 1995 Jun; 113(6):712-4. PubMed ID: 7786208
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
    Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A
    Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713
    [No Abstract]   [Full Text] [Related]  

  • 6. Apraclonidine in the management of glaucomatocyclitic crisis.
    Muthusamy P
    Eye (Lond); 1994; 8 ( Pt 3)():367-8. PubMed ID: 7958055
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
    Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
    Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
    Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iopidine in the control of intraocular pressure after glaucoma laser treatment].
    Stîngu C; Cristescu A; Dărăban C; Ioniţă M; Serghiescu S
    Oftalmologia; 2001; 54(4):32-5. PubMed ID: 12035597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine.
    Lewis R; Perkins TW; Gangnon R; Kaufman PL; Heatley GA
    Ophthalmology; 1998 Dec; 105(12):2256-9. PubMed ID: 9855156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes.
    Chung HS; Shin DH; Birt CM; Kim C; Lee D; Levin DS; Hakimzadeh R; Juzych MS
    Ophthalmology; 1997 Nov; 104(11):1921-5. PubMed ID: 9373127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
    Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
    Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
    Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apraclonidine prophylaxis for postcycloplegic intraocular pressure spikes.
    Hill RA; Minckler DS; Lee M; Heuer DK; Baerveldt G; Martone JF
    Ophthalmology; 1991 Jul; 98(7):1083-6. PubMed ID: 1679917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
    Nagasubramanian S; Hitchings RA; Demailly P; Chuniaud M; Pannarale MR; Pecori-Giraldi J; Stodtmeister R; Parsons DG
    Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
    Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
    Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of topical allergic reactions to 1% apraclonidine.
    Feibel RM
    Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.